Laurie Welton, DO
Infectious Disease · Sebastian, FLNPI 1215914353
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,076 of the $6,715 with a category attached, or 60.7%. 25 manufacturers reported payments, led by AbbVie at 41.6% of the total. Reporting peaked in 2019 at $3,361 and has fallen 98.8% since, to $40 in 2025.
Across 217 payments — averaging $30.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$470
- Gilead$456
- Insmed, Inc.$440
- Merck$384
- Cumberland Pharmaceuticals, Inc.$346
- plus $2K from 19 others
Across 39 payments — averaging $1885.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Paratek Pharmaceuticals, Inc.$43K
- Insmed, Inc.$14K
- Redhill Biopharma Inc.$14K
- Mannkind Corporation$2K
What the payments were for
- Speaking & faculty fees$2,30034%
- Travel & lodging$2053%
- Food & beverage$4,07661%
- Education$1342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $2,792 |
| Johnson & Johnson | 62 | $470 |
| Gilead | 13 | $456 |
| Insmed, Inc. | 28 | $440 |
| Merck | 22 | $384 |
| Cumberland Pharmaceuticals, Inc. | 9 | $346 |
| Viiv Healthcare Company | 18 | $334 |
| Amgen(2 entities) | 13 | $331 |
| Paratek Pharmaceuticals, Inc. | 12 | $318 |
| Shionogi Inc | 4 | $196 |
| Daiichi Sankyo Inc. | 6 | $141 |
| Janssen Scientific Affairs, LLC | 1 | $101 |
| Janssen Products, LP | 1 | $99 |
| Melinta Therapeutics, LLC | 3 | $60 |
| Astellas Pharma US Inc | 2 | $54 |
| Kerecis Limited | 2 | $40 |
| Lifenet Health | 1 | $24 |
| Nabriva Therapeutics, PLC | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Pfizer | 1 | $11 |
| Next Science LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,715 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $214,546 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 25 | $130,986 |
| DovatoDolutegravir Sodium/Lamivudine | 41 | $120,837 |
| IsentressRaltegravir Potassium | 46 | $98,976 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 22 | $80,312 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 17 | $74,833 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 20 | $71,304 |
| JulucaDolutegravir/Rilpivirine | 18 | $66,286 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 11 | $50,931 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $43,705 |
| Etravirine | 26 | $28,557 |
| Daptomycin | 21 | $14,670 |
| Vancomycin Hcl | 62 | $13,892 |
| Cefepime Hcl | 20 | $2,882 |
| Doxycycline Hyclate | 95 | $2,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Triumeq, Juluca | $334 | $267,43681 claims |
| Insmed, Inc.Arikayce | $440 | $214,54614 claims |
| GileadBiktarvy, Genvoya | $456 | $205,82042 claims |
| MerckIsentress | $384 | $98,97646 claims |
| Johnson & JohnsonComplera | $470 | $71,30420 claims |
| Janssen Products, LPSymtuza | $99 | $50,93111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Sebastian
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Christopher CooperAltamonte Springs$278K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
- Sally AlrabaaTampa$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.